Challenging store traffic trends, weak sales and pressured margins will be the catalysts for store closures to rise once again, UBS said.

Banks finally got a long-awaited boost to interest rates this year after a decade of toiling in a low-rate environment. It didn’t go as planned.

Analyst Chris Shibutani initiated the stock with a buy rating, saying the company has a promising new oral treatment in development for plaque psoriasis.